title: Serendipity in anticancer drug discovery.
abstract: It was found that the discovery of 5.8% (84/1437) of all drugs on the market involved serendipity. Of these drugs, 31 (2.2%) were discovered following an incident in the laboratory and 53 (3.7%) were discovered in a clinical setting. In addition, 263 (18.3%) of the pharmaceuticals in clinical use today are chemical derivatives of the drugs discovered with the aid of serendipity. Therefore, in total, 24.1% (347/1437) of marketed drugs can be directly traced to serendipitous events confirming the importance of this elusive phenomenon. In the case of anticancer drugs, 35.2% (31/88) can be attributed to a serendipitous event, which is somewhat larger than for all drugs. The therapeutic field that has benefited the most from serendipity are central nervous system active drugs reflecting the difficulty in designing compounds to pass the blood-brain-barrier and the lack of laboratory-based assays for many of the diseases of the mind.
authors.affiliation: Emily Hargrave-Thomas, Auckland Bioengineering Institute, The University of Auckland, Auckland 1142, New Zealand.
authors.forename: Emily
authors.initials: E
authors.lastname: Hargrave-Thomas
authors.forename: Bo
authors.initials: B
authors.lastname: Yu
authors.forename: Jóhannes
authors.initials: J
authors.lastname: Reynisson